The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia
Abstract
Key Points: MYD88 L265P is a widely expressed somatic mutation in WM patients that supports NF-κB signaling through stimulation of BTK and IRAK 1/4. Combined suppression of BTK and IRAK in MYD88 L265P expressing WM cells promotes synergistic inhibition of NF-κB signaling and WM cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Advanced in the clinical development pathway are inhibitors of BTK kinase activity whose prototype ibrutinib is a potent inducer of apoptosis of MYD88 L265P-expressing WM cells,(25) with encouraging activity observed in several WM patients included in a phase 1 study as well as in an ongoing phase 2 clinical trial.(31…”
BackgroundHelical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling
Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111
Cited by
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., Meid, K., & Yang, G. (2020) · Blood · doi:10.1182/blood.2020006288 · Cited by 909
Self-citationRole of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
Kawai, T., Ikegawa, M., Ori, D., & Akira, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.004 · Cited by 528
Hunter, Z. R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R. J., Tripsas, C., Patterson, C. J., Sheehy, P., et al. (2014) · Blood · doi:10.1182/blood-2013-09-525808 · Cited by 488
Self-citation
Metadata
- Authors
- Yang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R. J., Patterson, C. J., Buhrlage, S. J., Gray, N., Tai, Y.-T., Anderson, K. C., Hunter, Z. R., & Treon, S. P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-08-15
- Volume
- 122
- Issue
- 7
- Pages
- 1222-1232
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2006422013
- Cited by
- 352
- References
- 3
- FWCI
- 16.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. https://app.cochat.ai/papers/10.1182/blood-2012-12-475111
- The paper
- Yang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R. J., Patterson, C. J., Buhrlage, S. J., Gray, N., Tai, Y.-T., Anderson, K. C., Hunter, Z. R., & Treon, S. P. (2013). A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. https://doi.org/10.1182/blood-2012-12-475111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
